cc-401
Myeloid Leukemia
Celgene CorporationSmall moleculePhase 1Dormant
CC
41/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 81/ 100
Competitive context
32 Active assets in the Myeloid Leukemia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Fludarabine M.D. Anderson Cancer Center | Phase 2/3 | BBB |
Cyclophosphamide Actinium Pharmaceuticals | Phase 2/3 | BB |
FILGRASTIM M.D. Anderson Cancer Center | Phase 2 | BB |
Cytosin-Arabinosid M.D. Anderson Cancer Center | Phase 3 | BB |
Rapamycin Masonic Cancer Center, University of Minnesota | Phase 2 | BB |
View all 50 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →